Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced non-small- cell lung cancer: A multicenter, randomized, open-label phase II study

OncoTargets and Therapy

Volumn 7, Issue , 2014, Pages 1051-1060

  Govind Babu, K ^a   Prabhash, Kumar ^b   Vaid, Ashok K ^c   Sirohi, Bhawna ^c   Diwakar, Ravi B ^d   Rao, Raghunadha ^e   Kar, Madhuchanda ^f   Malhotra, Hemant ^g   Nag, Shona ^h   Goswami, Chanchal ⁱ   Raina, Vinod ^j   Mohan, Ravi ^k  

^a KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY   (India)

^b TATA MEMORIAL HOSPITAL   (India)

^c ARTEMIS HOSPITAL   (India)

^d Bangalore Institute of Oncology   (India)

^e NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

^f B R Singh Hospital   (India)

^g Birla Cancer Center   (India)

^h JEHANGIR HOSPITAL   (India)

ⁱ B P Poddar Hospital and Medical Research Ltd   (India)

^j INSTITUTE ROTARY CANCER HOSPITAL   (India)

^k King George Hospital   (India)

more..

Author keywords

Carboplatin; Docetaxel; Epidermal growth factor receptor; Nimotuzumab; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; DOCETAXEL; NIMOTUZUMAB;

ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; ASTHENIA; BACKACHE; CANCER CHEMOTHERAPY; CANCER STAGING; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EFFICACY EVALUABLE SET; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROENTERITIS; HUMAN; INTENTION TO TREAT ANALYSIS; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; OROPHARYNX PAIN; OVERALL SURVIVAL; PAIN; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; STATISTICAL ANALYSIS; THORAX PAIN; VOMITING;

EID: 84902485176     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S63168     Document Type: Article

References (32)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
2. Boland W, Bebb G. The emerging role of nimotuzumab in the treatment of non-small cell lung cancer. Biologics. 2010; 4: 289-298.
3. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346: 92-98.
4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235: 177-182.
5. Hanawa M, Suzuki S, Dobashi Y, et al. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer. 2006; 118: 1173-1180.
6. Schlomm T, Kirstein P, Iwers L, et al. Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. Clin Cancer Res. 2007; 13: 6579-6584.
7. Hirsch FR, Varella-Garcia M, Bunn P Jr, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003; 21: 3798-3807.
8. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 2129-2139.
9. Díaz A, Lage A. Therapies based on inhibitors of the epidermal growth factor receptor: reaching for the future. Biotecnol Apl. 2007; 24: 10-18.
10. Pirker R, Filipits M. Monoclonal antibodies against EGFR in non-small cell lung cancer. Crit Rev Oncol Hematol. 2011; 80: 1-9.
11. Gerber DE. EGFR inhibition in the treatment of non-small cell lung cancer. Drug Dev Res. 2008; 69: 359-372.
12. Prewett M, Rockwell P, Rockwell RF, et al. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother Emphasis Tumor Immunol. 1996; 19: 419-427.
13. Pazdur R. FDA approval for cetuximab: National Cancer Institute. Available from: http://www. cancer. gov/cancertopics/druginfo/fda-cetuximab. Accessed October 24, 2012.
14. Pazdur R. FDA Approval for panitumumab: National Cancer Institute. Available from: http://www. cancer. gov/cancertopics/druginfo/fda-panitumumab. Accessed October 24, 2012.
15. Agero AL, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol. 2006; 55: 657-670.
16. Boland WK, Bebb G. Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity. Expert Opin Biol Ther. 2009; 9: 1199-1206.
17. Mateo C, Moreno E, Amour K, Lombardero J, Harris W, Pérez R. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. Immunotechnology. 1997; 3: 71-81.
18. Takeda M, Okamoto I, Nishimura Y, Nagakawa K. Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer. Lung Cancer Targets Ther. 2011; 2: 59-67.
19. Crombet T, Osorio M, Cruz T, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol. 2004; 22: 1646-1654.
20. Rodriguez MO, Rivero TC, del Castillo Bahi R, et al. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol Ther. 2010; 9: 343-349.
21. Choi HJ, Sohn JH, Lee CG, et al. A phase I study of nimotuzumab in combination with radiotherapy in stages IIB-IV non-small cell lung cancer unsuitable for radical therapy: Korean results. Lung Cancer. 2011; 71: 55-59.
22. Bebb G, Smith C, Rorke S, et al. Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy. Cancer Chemother Pharmacol. 2011; 67: 837-845.
23. Wang HQ, Ren Y, Qian ZZ, et al. Nimotuzumab combined with gemcitabine and cisplatin as second-line chemotherapy for advanced non-small-cell lung cancer. Thoracic Cancer. 2012; 3: 72-78. Available from: http://onlinelibrary. wiley. com/doi/10. 1111/j. 1759-7714. 2011. 00083. x/abstract. Accessed May 30, 2014.
24. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
25. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009; 373: 1525-1531.
26. Lynch TJ, Patel T, Dreisbach L, et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol. 2010; 28: 911-917.
27. Socinski MA, Raju RN, Stinchcombe T, et al. Randomized, phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer. J Thorac Oncol. 2010; 5: 1963-1969.
28. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 2003; 21: 3016-3024.
29. Perez R, Moreno E, Garrido G, Crombet T. EGFR-targeting as a biological therapy: understanding nimotuzumab's clinical effects. Cancer. 2011; 3: 2014-2031.
30. Garrido G, Tikhomirov IA, Rabasa A, et al. Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile. Cancer Biol Ther. 2011; 11: 373-382.
31. Talavera A, Friemann R, Gomez-Puerta S, et al. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res. 2009; 69: 5851-5859.
32. Thatcher N, Heighway J. Maintenance and consolidation therapy in patients with unresectable stage III/IV non-small cell lung cancer. Oncologist. 2010; 15: 1034-1042.